Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Athersys Inc (ATHX)

Athersys Inc (ATHX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 211,500
  • Shares Outstanding, K 156,667
  • Annual Sales, $ 24,290 K
  • Annual Income, $ -24,280 K
  • 60-Month Beta 0.32
  • Price/Sales 8.77
  • Price/Cash Flow N/A
  • Price/Book 7.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.22 +14.75%
on 11/08/19
1.43 -2.10%
on 11/14/19
+0.04 (+2.94%)
since 10/15/19
3-Month
1.22 +14.75%
on 11/08/19
1.52 -7.89%
on 09/13/19
+0.17 (+13.82%)
since 08/15/19
52-Week
1.20 +16.67%
on 08/15/19
2.15 -34.88%
on 12/12/18
-0.49 (-25.93%)
since 11/15/18

Most Recent Stories

More News
Healios Receives Notification of Orphan Designation for Acute Respiratory Distress Syndrome Clinical Program

Athersys, Inc. (Nasdaq: ATHX) announced today that its collaborator in Japan, HEALIOS K.K. ("Healios") received notification this week from the Pharmaceutical Affairs and Food Sanitation Council ("PAFSC")...

ATHX : 1.39 (+2.96%)
Athersys Reports Third Quarter 2019 Results

Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended September 30, 2019.

ATHX : 1.39 (+2.96%)
Athersys to Host Third Quarter Financial Results Call

Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, November 6, 2019, and will host a conference call shortly thereafter...

ATHX : 1.39 (+2.96%)
Athersys to Present at 2019 Cell & Gene Meeting on the Mesa

Athersys, Inc. (NASDAQ: ATHX) announced today that Dr. Gil Van Bokkelen, Chairman and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 2 -4 in Carlsbad, California.

ATHX : 1.39 (+2.96%)
Athersys Reports Second Quarter 2019 Results

Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2019.

ATHX : 1.39 (+2.96%)
Athersys to Host Second Quarter Financial Results Call

Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, August 7, 2019, and will host a conference call shortly thereafter...

ATHX : 1.39 (+2.96%)
Global Translational Regenerative Medicines Market Outlook (2017-2026)

According to Stratistics MRC, the Global Translational Regenerative Medicines Market is growing at a CAGR of 13.9% from 2017 to 2026. Factors such as the increasing prevalence of degenerative diseases,...

ANIK : 60.09 (+0.54%)
ATHX : 1.39 (+2.96%)
BCLI : 3.75 (+1.35%)
CELGZ : 0.44 (-8.33%)
NVS : 90.03 (+0.58%)
Athersys to Present at Jefferies 2019 Healthcare Conference

Athersys, Inc. (NASDAQ: ATHX) announced today that Dr. Gil Van Bokkelen, Chairman and CEO, will present at the Jefferies 2019 Healthcare Conference taking place June 4-7, 2019 in New York City. Dr. Van...

ATHX : 1.39 (+2.96%)
Athersys to Participate in four Events at the International Society of Cell and Gene Therapy Conference

Athersys, Inc. (NASDAQ: ATHX) announced today its participation in several sessions at this year's International Society for Cell and Gene Therapy (ISCT) conference taking place May 29 - June 2, 2019 in...

ATHX : 1.39 (+2.96%)
Athersys Presents Data From Its Acute Respiratory Distress Syndrome Clinical Trial at American Thoracic Society International Conference

Athersys, Inc. (Nasdaq: ATHX) announced additional favorable data from its exploratory Phase 1/2 acute respiratory distress syndrome (ARDS) clinical trial. Dr. Geoff Bellingan, Medical Director at University...

ATHX : 1.39 (+2.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft.

See More Share

Trade ATHX with:

Business Summary

Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and...

See More

Key Turning Points

2nd Resistance Point 1.46
1st Resistance Point 1.40
Last Price 1.39
1st Support Level 1.32
2nd Support Level 1.30

See More

52-Week High 2.15
Fibonacci 61.8% 1.79
Fibonacci 50% 1.68
Fibonacci 38.2% 1.56
Last Price 1.39
52-Week Low 1.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar